Outcome of Board Meeting dated May 15, 2026, please refer the attached PDF for detailed information
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 1.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jupiter Life Line Hospitals reported audited FY26 consolidated results with revenue from operations of Rs. 14,997.87 million, up 15.15% from Rs. 13,024.02 million in FY25. Net profit grew marginally to Rs. 1,941.87 million from Rs. 1,937.54 million, while total comprehensive income stood at Rs. 1,945.89 million. The board declared an interim dividend of Rs. 1 per share (10% on face value) with record date May 22, 2026. Key corporate actions include a stock split subdividing 1 share of Rs. 10 into 5 shares of Rs. 2 each, change in designation of Dr. Ajay Thakker as Chairman and Whole-Time Director, and appointments of new internal and cost auditors. The statutory auditors issued an unmodified opinion on both standalone and consolidated financial statements.
Revenue growth of 15.15% is positive but below expectations; PAT growth of just 0.22% is essentially flat. The stock split may improve retail accessibility and liquidity. Shareholders receive a modest dividend amid muted profit growth.